<DOC>
	<DOCNO>NCT00002831</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Phase I/II trial study effectiveness high-dose chemotherapy plus peripheral stem cell transplantation treat patient chronic myelogenous acute leukemia .</brief_summary>
	<brief_title>Chemotherapy Plus Peripheral Stem Cell Transplantation Treating Patients With Chronic Myelogenous Acute Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose decitabine combination busulfan cyclophosphamide patient hematologic malignancy . II . Establish pharmacokinetics decitabine busulfan patient population . III . Determine effectiveness combination achieve durable complete remission patient chronic myelogenous leukemia ( CML ) blast crisis acute myelogenous leukemia ( AML ) relapse undergo allogeneic stem cell transplantation . OUTLINE : In cohort 3 , patient receive escalate dos decitabine ( DAC ) IV 4 hour day -8 -7 . Busulfan administer orally every 6 hour consecutive day -6 -4 . Cyclophosphamide give vein ( IV ) 1 hour consecutive day -3 -2 . The maximum tolerate dose DAC define dose 2 patient experience dose limit toxicity . Donors receive filgrastim subcutaneously ( SQ ) daily every 12 hour start 2-4 day prior first stem cell collection DAC infusion . Leukapheresis conduct daily . If insufficient number cell collect , blood marrow harvest supplementation . Stem cell infuse day 0 . For graft v host disease prophylaxis ( GVHD ) , patient receive tacrolimus IV begin one day stem cell infusion , orally follow tolerance tacrolimus . Patients intolerant tacrolimus receive cyclosporine IV begin day -2 , orally follow tolerance engraftment . All patient receive methylprednisolone give accord clinical grade GVHD procedure . For CNS prophylaxis , methotrexate give intrathecally intraventricularly monthly , begin second month eighth month treatment . Allogeneic patient follow end 1 year . PROJECTED ACCRUAL : An estimated 30 allogeneic recipient recruit 2 year expect study duration 2-3 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute leukemia past first remission induction failure Chronic myelogenous leukemia accelerate phase blast crisis PATIENT CHARACTERISTICS : Age : 15 55 Performance status : Zubrod 02 Life expectancy : Life expectancy severely limited concurrent illness Hematopoietic : Not specify Hepatic : No evidence chronic active hepatitis cirrhosis Bilirubin great 2 time upper limit normal SGPT great 4 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : Left ventricular ejection fraction least 50 % No uncontrolled arrhythmias symptomatic cardiac disease Pulmonary : FEV1 , FVC , DLCO least 50 % No symptomatic pulmonary disease Other : Related donor HLAidentical require No effusion ascites great 1 L prior drainage HIV negative Not pregnant No active CNS disease PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
</DOC>